Stay updated on Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial page.

Latest updates to the Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page now includes a new site revision tag: Revision: v3.4.2. The older funding-status notice and the earlier Revision: v3.4.1 text have been removed.SummaryDifference0.3%

- Check21 days agoChange DetectedAdded a government funding lapse notice regarding NIH site status and updated the site revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.3%

- Check28 days agoChange DetectedA new 'Show glossary' option was added to the page interface, and several metadata labels were updated (e.g., 'Last Update Submitted that Met QC Criteria', 'No FEAR Act data') with the revision note showing 'Revision: v3.4.0'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check64 days agoChange DetectedLocations section expanded to list multiple new sites (Beijing Municipality, Fujian, Jiangsu, Jilin, Shanxi, Zhejiang, Kuala Lumpur, Gyeonggi-do) and corresponding individual location subsections were removed, along with the HHS Vulnerability Disclosure link.SummaryDifference0.7%

- Check85 days agoChange DetectedThe page footer revision label updated from v3.3.1 to v3.3.2. No other content or study details were changed.SummaryDifference0.0%

- Check92 days agoChange DetectedPublications section now states that publications are automatically filled in from PubMed, and the page revision is updated to v3.3.1.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Paclitaxel in Asian Gastric Cancer Clinical Trial page.